

INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE  
PROSECUTION OF THE SUBJECT APPLICATION

Applicants: T. Takagi et al. Attorney Docket No.: SNKYO126512  
Application No.: 10/555,076 International Application No.: PCT/JP2004/06100  
Mailed: October 28, 2005 International Filing Date: April 27, 2004  
Title: ADIPONECTIN PRODUCTION ENHANCER

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
/T.B./	U1	4,231,938	A	11/04/1980	Monaghan et al.
	U2	4,346,227	A	08/24/1982	Terahara et al.
	U3	4,444,784	A	04/24/1984	Hoffman et al.
	U4	4,739,073	A	04/19/1988	Kathawala
	U5	5,006,530	A	04/09/1991	Angerbauer et al.
	U6	5,260,440	A	11/09/1993	Hirai et al.
	U7	5,273,995	A	12/28/1993	Roth
	U8	5,854,259	A	12/29/1998	Fujikawa et al.
↓	U9	5,856,336	A	01/05/1999	Fujikawa et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
/T.B./	F1	JP 9-71540	A	03/18/1997	JP		
/T.B./	F2	WO 00/56403	A1	09/28/2000	WO		
/T.B./	F3	WO 01/76573	A2	10/18/2001	WO		

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
/T.B./	O1	Arita, Y., et al., "Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB-Binding Protein and Regulates Growth Factor-Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell," <i>Circulation</i> 105:2893-2898, June 18, 2002.

\*Examiner Cite  
Initial No.

Initial	Cite No.
/T.B./	O2 Arita, Y., et al., "Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity," <i>Biochemical and Biophysical Research Communications</i> 257(1):79-83, 1999.
	O3 Bellosa, S., et al., "Pleiotropic Effects of Statins in Atherosclerosis and Diabetes," <i>Diabetes Care</i> 23(Suppl. 2), April 2000, 1 p. (abstract), retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10860194&query_hl=2&itool=pubmed_DocSum> [retrieved October 5, 2005].
	O4 Berg, A.H., et al., "The Adipocyte-Secreted Protein Acrp30 Enhances Hepatic Insulin Action," <i>Nature Medicine</i> 7(8):947-953, August 2001.
	O5 Chaudhuri, A., "Vascular Reactivity in Diabetes Mellitus," <i>Current Diabetes Reports</i> 2:305-310, 2002.
	O6 Cingözbay, B.Y., et al., "Effects of Fluvastatin Treatment on Insulin Sensitivity in Patients With Hyperlipidaemia," <i>Journal of International Medical Research</i> 30:21-25, 2002.
	O7 Combs, T.P., et al., "Endogenous Glucose Production Is Inhibited by the Adipose-Derived Protein Acrp30," <i>Journal of Clinical Investigation</i> 108(12):1875-1881, December 2001.
	O8 Freeman, D.J., et al., "Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study," <i>Circulation</i> 103:357-362, January 23, 2001.
	O9 Hotta, K., et al., "Circulating Concentrations of the Adipocyte Protein Adiponectin Are Decreased in Parallel With Reduced Insulin Sensitivity During the Progression to Type 2 Diabetes in Rhesus Monkeys," <i>Diabetes</i> 50:1126-1133, May 2001.
	O10 Komai, T., "Effect of Statins on Glucose Metabolism," <i>Bio Clinica</i> 17(10):68-73, 2002.
	O11 Kondo, H., et al., "Association of Adiponectin Mutation With Type 2 Diabetes: A Candidate Gene for the Insulin Resistance Syndrome," <i>Diabetes</i> 51:2325-2328, July 2002.
↓	O12 Lindsay, R.S., et al., "Adiponectin and Development of Type 2 Diabetes in the Pima Indian Population," <i>Lancet</i> 360:57-58, July 6, 2002.

\*Examiner Cite  
Initial No.

Initial	Cite No.
/T.B./	O13 MacMahon, S., et al., "Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis, Levels on the Progression of Carotid Atherosclerosis: Results of the LIPID Atherosclerosis Substudy," <i>Circulation</i> 97:1784-1790, May 12, 1998.
	O14 Maeda, K., et al., "cDNA Cloning and Expression of Novel Adipose Specific Collagen-Like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)," <i>Biochemical and Biophysical Research Communications</i> 221(2):286-289, 1996.
	O15 Maeda, N., et al., "PPAR $\gamma$ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein," <i>Diabetes</i> 50:2094-2099, September 2001.
	O16 Mangaloglu, L., et al., "Treatment With Atorvastatin Ameliorates Hepatic Very-Low-Density Lipoprotein Overproduction in an Animal Model of Insulin Resistance, the Fructose-Fed Syrian Golden Hamster: Evidence That Reduced Hypertriglyceridemia Is Accompanied By Improved Hepatic Insulin Sensitivity," <i>Metabolism</i> 51(4):409-418, April 2002.
	O17 McFarlane, S.I., et al., "Clinical Review 145: Pleiotropic Effects of Statins: Lipid Reduction and Beyond," <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 87(4):1451-1458, April 2002.
	O18 McVeigh, G.E., and J.N. Cohn, "Endothelial Dysfunction and the Metabolic Syndrome," <i>Current Diabetes Reports</i> 3:87-92, 2003.
	O19 Okamoto, Y., et al., "Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice," <i>Circulation</i> 106:2767-2770, November 26, 2002.
	O20 Ouchi, N., et al., "Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages," <i>Circulation</i> 103:1057-1063, February 27, 2001.
	O21 Ouchi, N., et al., "Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF- $\kappa$ B Signaling Through a cAMP-Dependent Pathway," <i>Circulation</i> 102:1296-1301, September 12, 2000.
	O22 Ouchi, N., et al., "Novel Modulator for Endothelial Adhesion Molecules: Adipocyte-Derived Plasma Protein Adiponectin," <i>Circulation</i> 100:2473-2476, December 21/28, 1999.
	O23 Paolisso, G., et al., "Effects of Simvastatin and Atorvastatin Administration on Insulin Resistance and Respiratory Quotient in Aged Dyslipidemic Non-Insulin Dependent Diabetic Patients," <i>Atherosclerosis</i> 150:121-127, 2000.

*Examiner Initial	Cite No.
<u>T.B./</u>	O24 Reaven, G.M., "Role of Insulin Resistance in Human Disease," <i>Diabetes</i> 37:1595-1607, December 1988.
—	O25 Ross, R., "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s," <i>Nature</i> 362:801-809, April 29, 1993.
—	O26 Shepherd, J., et al., "Pravastatin in Elderly Individuals at Risk of Vascular Disease (Prosper): a Randomised Controlled Trial," <i>Lancet</i> 360:1623-1630, November 23, 2003.
—	O27 Sorisky, A., "Molecular Links Between Obesity and Cardiovascular Disease," <i>American Journal of Therapeutics</i> 9:516-521, 2002.
—	O28 Weyer, C., et al., "Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association With Insulin Resistance and Hyperinsulinemia," <i>Journal of Clinical Endocrinology &amp; Metabolism</i> 86(5):1930-1935, 2001.
—	O29 Yamauchi, T., et al., "The Fat-Derived Hormone Adiponectin Reverses Insulin Resistance Associated With Both Lipoatrophy and Obesity," <i>Nature Medicine</i> 7(8):941-946, August 2001.
—	O30 Yokota, T., et al., "Adiponectin, a New Member of the Family of Soluble Defense Collagens, Negatively Regulates the Growth of Myelomonocytic Progenitors and the Functions of Macrophages," <i>Blood</i> 96(5):1723-1732, September 1, 2000.
↓	O31 Zoccali, C., et al., "Adiponectin, Metabolic Risk Factors, and Cardiovascular Events Among Patients With End-Stage Renal Disease," <i>Journal of the American Society of Nephrology</i> 13:134-141, 2002.

**Examiner**

/Timothy Betton/

**Date Considered**

03/11/2009

\*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:mk/dmg